search
Back to results

Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation

Primary Purpose

End Stage Renal Disease, Acute Renal Failure, Hemodialysis Catheter Infection

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Sodium Bicarbonate Catheter Lock Solution
Normal Saline Catheter Lock Solution
Sponsored by
Coney Island Hospital, Brooklyn, NY
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for End Stage Renal Disease focused on measuring Central Venous Catheters, End Stage Renal Disease, Hemodialysis, Catheter-related infection, Catheter loss due to clot formation, Acute Renal Failure

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients presenting over the age of 18 requiring hemodialysis via CVCs were eligible.

Exclusion Criteria:

  • Having a poor venous system with inadequate blood flow for appropriate HD.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Normal Saline Catheter Lock Solution Group

    Sodium Bicarbonate Catheter Lock Solution

    Arm Description

    Patients receiving normal saline catheter locking solution

    Patients receiving sodium bicarbonate catheter locking solution

    Outcomes

    Primary Outcome Measures

    Lumen Clot Formation
    Catheter Loss Due to Lumen Clot Formation
    Catheter Related Infection
    Catheter Loss Due to Catheter Related Infection
    Malfunction
    Catheter Loss Due to Malfunction
    Overall Cause
    Catheter Loss Due to All Causes

    Secondary Outcome Measures

    Death
    Number of deaths reported during the study period
    Arrhythmia
    Incidence of significant arrhythmia during dialysis requiring urgent intervention
    Hemodynamic Instability
    Incidence of extreme hypotension or hypertension requiring urgent intervention

    Full Information

    First Posted
    July 12, 2018
    Last Updated
    August 8, 2018
    Sponsor
    Coney Island Hospital, Brooklyn, NY
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03627884
    Brief Title
    Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
    Official Title
    Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    October 1, 2016 (Actual)
    Primary Completion Date
    March 30, 2018 (Actual)
    Study Completion Date
    March 30, 2018 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Coney Island Hospital, Brooklyn, NY

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Prospective, randomized, comparative clinical and open-label trial comparing sodium bicarbonate catheter lock solution (SBCLS) to normal saline catheter lock solution (NSCLS) use in HD patients with central venous catheters (CVC).
    Detailed Description
    A randomized, comparative clinical, open-label trial at Coney Island Hospital, in Brooklyn, NY. The study period was between October 1, 2016 and March 30, 2018, a total of 546 days. All patients provided written informed consent before enrollment. The trial protocol was approved by Maimonides Medical Center Investigational Review Board: Study #2015-06-25-CIH. Patients presenting over the age of 18 requiring hemodialysis via CVCs were eligible. One patient was excluded due to having a poor venous system with inadequate blood flow for appropriate HD. No other patient was excluded from the study. A total of 451 patients undergoing HD with CVCs were included in the study. Patients had tunneled internal jugular vein (IJV) catheters, non-tunneled IJV catheters, and non-tunneled femoral vein catheters. All patients were randomly assigned based on simple sequential order into one of two groups: NSCLS (n = 226) and SBCLS (n = 225). NSCLS patients were assigned between October 1, 2016 and June 30, 2017. SBCLS patients were assigned between July 1 2017 and March 30, 2018. Recruitment ended based on the similar number of enrolled participants between groups. A primary or co-investigator enrolled the participant into the trial and assigned the participant to the intervention at the time of presentation. Both groups received heparin-free HD treatment. Before each HD treatment, catheters and connections were inspected for leaks, evidence of damage, exit-site infection and tunnel infection. Intraluminal SBCLS or NSCLS lock solution was removed before connecting the HD catheter to a dialysis machine prior to any treatment. During each treatment, patients were monitored for complications and standard care was provided to every patient. After each treatment, blood was rinsed from dialysis lines with NS solution back to the patient. Upon the conclusion of treatment, all catheters were flushed and locked with 10 mL of NSCLS or SBCLS, respective of their groups. Approximately 2 mL of the injected solution remained locked within the catheter. Catheter exit site dressing changes occurred after each HD treatment. For patients that had clotted catheters, thrombolytic therapy was not instituted. Risk assessment performed by our hospital's risk management department determined that the net risk of thrombolytic use in their opinion was greater than the risk of catheter replacement by our qualified operators. CVCs used in the study varied according to the patient's needs and consisted of Mahurkar non-tunneled catheters and Palindrome tunneled catheters. All CVCs were inserted by an expert operator under strict aseptic protocol. Catheter care was performed by trained dialysis staff according to our hospital's Administrative Policy and Procedure Manual. At the end of dialysis, all catheters were flushed and locked with one of two solutions. SBCLS contained 7.5% or 8.4% SB at a pH of 7.0-8.5, and was used to lock SBCLS-group catheters. NSCLS contained 0.9% sodium chloride at a pH 4.5-7.0, and was used to lock NSCLS-group patient catheters. Both are sterile non-pyrogenic solutions.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    End Stage Renal Disease, Acute Renal Failure, Hemodialysis Catheter Infection, Hemodialysis Complication, Hemodialysis Access Failure, Hemodialysis Catheter-Associated Bacteremia
    Keywords
    Central Venous Catheters, End Stage Renal Disease, Hemodialysis, Catheter-related infection, Catheter loss due to clot formation, Acute Renal Failure

    7. Study Design

    Primary Purpose
    Prevention
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    451 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Normal Saline Catheter Lock Solution Group
    Arm Type
    Active Comparator
    Arm Description
    Patients receiving normal saline catheter locking solution
    Arm Title
    Sodium Bicarbonate Catheter Lock Solution
    Arm Type
    Active Comparator
    Arm Description
    Patients receiving sodium bicarbonate catheter locking solution
    Intervention Type
    Drug
    Intervention Name(s)
    Sodium Bicarbonate Catheter Lock Solution
    Intervention Description
    Using Sodium Bicarbonate Catheter Lock Solution
    Intervention Type
    Drug
    Intervention Name(s)
    Normal Saline Catheter Lock Solution
    Intervention Description
    Using Sodium Bicarbonate Catheter Lock Solution
    Primary Outcome Measure Information:
    Title
    Lumen Clot Formation
    Description
    Catheter Loss Due to Lumen Clot Formation
    Time Frame
    Approximately 18 months
    Title
    Catheter Related Infection
    Description
    Catheter Loss Due to Catheter Related Infection
    Time Frame
    Approximately 18 months
    Title
    Malfunction
    Description
    Catheter Loss Due to Malfunction
    Time Frame
    Approximately 18 months
    Title
    Overall Cause
    Description
    Catheter Loss Due to All Causes
    Time Frame
    Approximately 18 months
    Secondary Outcome Measure Information:
    Title
    Death
    Description
    Number of deaths reported during the study period
    Time Frame
    Approximately 18 months
    Title
    Arrhythmia
    Description
    Incidence of significant arrhythmia during dialysis requiring urgent intervention
    Time Frame
    Approximately 18 months
    Title
    Hemodynamic Instability
    Description
    Incidence of extreme hypotension or hypertension requiring urgent intervention
    Time Frame
    Approximately 18 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients presenting over the age of 18 requiring hemodialysis via CVCs were eligible. Exclusion Criteria: Having a poor venous system with inadequate blood flow for appropriate HD.

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    30668833
    Citation
    El-Hennawy AS, Frolova E, Romney WA. Sodium bicarbonate catheter lock solution reduces hemodialysis catheter loss due to catheter-related thrombosis and blood stream infection: an open-label clinical trial. Nephrol Dial Transplant. 2019 Oct 1;34(10):1739-1745. doi: 10.1093/ndt/gfy388.
    Results Reference
    derived

    Learn more about this trial

    Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation

    We'll reach out to this number within 24 hrs